Preventing disturbing migraine aura with lamotrigine: An open study

Headache

Volumn 44, Issue 10, 2004, Pages 1024-1028

  Pascual, Julio ^a   Caminero, Ana B ^b   Mateos, Valentín ^c   Roig, Carlos ^d   Leira, Rogelio ^e   García Moncó, Carlos ^f   Laínez, Miguel J ^g  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL NUESTRA SEÑORA DE SONSOLES   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e Instituto de Salud Carlos III   (Spain)

^f HOSPITAL DE GALDAKAO   (Spain)

^g NONE

Author keywords

Lamotrigine; Migraine aura; Migraine prophylaxis

Indexed keywords

LAMOTRIGINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DYSPHASIA; FEMALE; FOLLOW UP; HEMIANOPIA; HEMIPLEGIA; HUMAN; LABORATORY TEST; LEFT HEMISPHERE; MIGRAINE; PARESTHESIA; PRIORITY JOURNAL; QUESTIONNAIRE; RASH; SPEECH DISORDER; TREATMENT FAILURE; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

ADULT; AGED; CALCIUM CHANNEL BLOCKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE WITH AURA; TREATMENT OUTCOME; TRIAZINES;

EID: 8844247031     PISSN: 00178748     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2004.04198.x     Document Type: Article

References (26)

1. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia. 2004(suppl 1):1-160.
2. Bates D, Ashford E, Dawson R, et al. Subcutaneous sumatriptan during the migraine aura. Sumatriptan Aura Study Group. Neurology. 1994;44:1587-1592.
3. Silberstein SD, McCrory DC. Ergotamine and dihydroergotamine: history, pharmacology and efficacy. Headache. 2002;43:144-146.
4. Yu W, Horowitz SH. Familial hemiplegic migraine and its abortive therapy with intravenous verapamil. Neurology. 2001;57:1732-1733.
5. Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology. 2003;60:120-121.
6. Rozen TD. Treatment of a prolonged migrainous aura with intravenous furosemide. Neurology. 2000;55:732-733.
7. Kaube H, Herzog J, Kaufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 2000;55:139-141.
8. Prendes JL. Considerations on the use of propranolol in complicated migraine. Headache. 1980;20:93-95.
9. Gilbert GJ. An occurrence of complicated migraine during propranolol therapy. Headache. 1982;22:81-83.
10. Bardwell A, Trott JA. Stroke in migraine as a consequence of propranolol. Headache. 1987;27:381-383.
11. Mendizabal JE, Greiner F, Hamilton WJ, Rothrock JF. Migrainous stroke causing thalamic infarction and amnesia during treatment with propranolol. Headache. 1997;37:594-596.
12. Rothrock JF. Successful treatment of persistent migraine aura with divalproex sodium. Neurology. 1997;48:261-262.
13. Lampl C, Bonelli S, Ransmayr G. Efficacy of topiramate in migraine aura prophylaxis: preliminary results of 12 patients. Headache. 2004;44:174-176.
14. Steiner TJ, Findley LJ, Yuen AWC. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia. 1997;17:109-112.
15. Chen WT, Fuh JL, Lu SR, Wang SJ. Persistent migrainous visual phenomena might be responsive to lamotrigine. Headache. 2001;41:823-825.
16. D'Andrea G, Granella F, Cadaldicini N, Manzoni GC. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open study. Cephalalgia. 1999;19:64-66.
17. Lampl C, Buzath A, Klinger D, Neuman K. Lamotrigine in the prophylactic treatment of migraine aura - a pilot study. Cephalalgia. 1999;19:58-63.
18. Lauritzen M. Pathophysiology of the migraine aura. Brain. 1994;117:199-210.
19. Castillo J, Martínez F, Leira R, Prieto JM, Lema M, Noya M. Changes in neuroexcitatory amino acids during and between migraine attacks. Neurología. 1994;9:42-45.
20. Martínez F, Castillo J, Rodríguez JR, Leira R, Noya M. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13:89-93.
21. Cananzi AR, D'Andrea G, Perini F, Zamberlan F, Welch KMA. Platelet and plasma levels of glutamate and glutamine in migraine with and without aura. Cephalalgia. 1995;15:132-135.
22. Welch KMA, D'Andrea G, Tepley N, Barkley G, Ramadan NM. The concept of migraine as a state of central neuronal hyperexcitability. Neurol Clin. 1990;8:817-828.
23. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther. 1993;266:829-835.
24. Leach MJ, Lees G, Riddal DR. Lamotrigine. Mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic Drugs, 4th edition. New York: Raven Press; 1995:861-819.
25. Stefani A, Spadoni F, Siniscalchi A, Bernardi G. Lamotrigine inhibits Ca2+ currents in cortical neurons: functional implications. Eur J Pharmacol. 1996;307:113-116.
26. Wang SJ, Tsai JJ, Gean PW. Lamotrigine inhibits depolarization-evoked Ca influx in dissociated amygdale neurons. Synapse. 1998;29:355-362.